ReviewJournal of clinical medicine2020
Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.The Cochrane database of systematic reviews · 2020Pooled it
- Cardiogenic Shock: Clinical Management, Outcomes and Future Directions.Journal of cardiovascular development and disease · 2026Review
- Cardiogenic shock and acute renal failure associated mortality trends in the United States: a retrospective analysis of death records from 1999 to 2023.BMC cardiovascular disorders · 2026Article
- Early use of levosimendan to improve survival and neurological outcomes after cardiac arrest with myocardial dysfunction: a protocol for a randomized controlled trial.Frontiers in cardiovascular medicine · 2026Article
- Comparative Efficacy of Noradrenaline vs. Other Vasopressors on Outcomes in Patients With Cardiogenic Shock - A Systematic Review and Meta-Analysis.Circulation reports · 2025Article
- Management of cardiogenic shock: state-of-the-art.Intensive care medicine · 2024Review
- The carbon monoxide prodrug oCOm-21 increases CaPhysiological reports · 2024Article
- Treatment of patients with multiple organ dysfunction syndrome (MODS) with an electromagnetic field coupled to biorhythmically defined impulse configuration: the MicrocircMODS study.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Levosimendan improves cardiac function, hemodynamics, and body inflammation in patients with acute myocardial infarction and heart failure.American journal of translational research · 2023Article
- Inotropic support in cardiogenic shock: who leads the battle, milrinone or dobutamine?Annals of medicine and surgery (2012) · 2022Review
- Evolving Presentation of Cardiogenic Shock: A Review of the Medical Literature and Current Practices.Cardiology and therapy · 2022Review
- Recent Advances in the Therapeutic Efficacy of Artesunate.Pharmaceutics · 2022Review
- A Clinical Update on Vasoactive Medication in the Management of Cardiogenic Shock.Clinical Medicine Insights. Cardiology · 2022Review
- Cardioprotective shock management: monitoring and supportive therapies.European heart journal supplements : journal of the European Society of Cardiology · 2021Article
- Vasoactive pharmacologic therapy in cardiogenic shock: a critical review.Journal of drug assessment · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasopressors and inotropes are routinely used in acute myocardial infarction (AMI) related cardiogenic shock (CS) to improve hemodynamics. We aimed to investigate the effect of routinely used vasopressor and inotropes on mortality in AMI related CS. A systematic search of MEDLINE, EMBASE and CENTRAL was performed up to 20 February 2019. Randomized and observational studies reporting mortality of AMI related CS patients were included. At least one group should have received the vasopressor/inotrope compared with a control group not exposed to the vasopressor/inotrope. Exclusion criteria were case reports, correspondence and studies including only post-cardiac surgery patients. In total, 19 studies (6 RCTs) were included, comprising 2478 CS patients. The overall quality of evidence was graded low. Treatment with adrenaline, noradrenaline, vasopressin, milrinone, levosimendan, dobutamine or dopamine was not associated with a difference in mortality between therapy and control group. We found a trend toward better outcome with levosimendan, compared with control (RR 0.69, 95% CI 0.47-1.00). In conclusion, we found insufficient evidence that routinely used vasopressors and inotropes are associated with reduced mortality in patients with AMI related CS. Considering the limited evidence, this study emphasizes the need for randomized trials with appropriate endpoints and methodology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.